Global
Contact Us
Net sales of CHF 11.1 billion (2.9% at CER1) – growth acceleration in H2 2025 (+3.6% CER1) Core EBIT increased to CHF 349.0 million (6.7% at CER1) – stronger H2 2025 (+8.1% CER1) Core EBIT margin expanded by 0.1 percentage points to 3.2% (5th consecutive year) Free Cash Flow of CHF 215.5 million Dividend proposal of CHF 2.50 per share (+6.4%)2 and 9 M&A transactions announced in 2025 Mid-term roadmap confirmed
DKSH and Tun Tauk Naing Manufacturing partner to launch the first FDA-approved Phyoe Mouk Blended Oil in Myanmar. Building on a successful partnership since 2022, the two companies continue to strengthen access to safe, high-quality cooking oil for households across Myanmar.
DKSH has expanded its food and beverage ingredients portfolio in Thailand through a distribution partnership with Kemin Food Technologies, a leading provider of food technologies. Under this collaboration, DKSH will strengthen Kemin’s presence in the Thai market by supporting food manufacturers with advanced solutions to enhance food safety, extend shelf life, and improve food quality. This agreement builds on the successful collaboration in Cambodia, Indonesia, Myanmar, the Philippines, and Vietnam.
DKSH enters a new partnership with Myanmar Food Hub Manufacturing Company Limited to introduce Umami Instant Noodles and Milaysan Mohinga Paste to the Myanmar market. This collaboration showcases DKSH Consumer Goods’ role in helping local manufacturers scale new brands and connecting Myanmar consumers with trusted kitchen staples through strong market execution.
DKSH has entered into a partnership with Pfizer to commercialize and distribute its anti‑infective therapies, marking a significant milestone in strengthening Malaysia’s access to vital, life‑saving treatments. This collaboration builds on DKSH’s existing partnerships with Pfizer in multiple markets in Southeast Asia further strengthening Pfizer’s footprint and execution capabilities across the region.
DKSH Malaysia has entered into a strategic partnership with AbbVie Sdn. Bhd. to provide commercial services for its leading ophthalmology portfolio within Malaysia’s pharmacy channel. This partnership builds on DKSH’s existing collaborations with AbbVie in Vietnam and Thailand, further strengthening AbbVie’s regional presence and commercial excellence in Asia’s eye care market.
DKSH has been recognized as a Great Place to Work® in 16 key markets, surpassing the number of certified markets in the previous year. DKSH has also been named one of the “Fortune 100 Best Companies to Work For™ Southeast Asia 2025”. These achievements reaffirm DKSH’s work environment and underscore its ongoing commitment to fostering a great corporate culture.
DKSH and Hygiena expand their strategic partnership to Thailand to deliver faster, science-based diagnostics that help industries safeguard quality, compliance, and consumer trust. This extension builds on the successful collaboration across several markets in Southeast Asia.
DKSH has entered into distribution agreement with Xcell Therapeutics, a specialist in chemically defined cell culture media, to strengthen access to advanced bioprocessing solutions in India. Through this partnership, DKSH will support Xcell Therapeutics’ growth in India’s rapidly expanding biotechnology and cytogenetic therapy market.
Reach out to our Group Media Relations team for any inquiries.
Head, Investor and Media Relations & Sustainability, and Head, Finance Healthcare Own Brands
Manager, Group Media Relations
Contact us to discover new opportunities.